JAK inhibitors for better management of rheumatic diseases

Speciality: Rheumatology


Speaker:

Prof. Anand N. Malaviya, | MD, FRCP (Lond.) Master ACR & APLAR, FACP, FICP, FAMS, FNASc

Dr Indrajit Agrawal | MD MRCP HOD Rheumatology

Dr Sanjiv Kapoor | MD, DM

Description:

A warm welcome to all the medical professionals in this interesting session of pioneering JAK science. We have Prof. Anand N. Malaviya, Dr Indrajit Agrawal, and Dr Sanjiv Kapoor to lead the session.

Immunological pathways play a crucial role in disease management especially in the case of rheumatological disease. Managing rheumatic diseases often becomes difficult and needs specialized attention which can be gained from this webinar.

The webinar will help in gaining important insights on JAK or Janus Kinase's family. The family includes Jak1, Jak2, Jak3, and Tyk2 which are involved in cell growth, development, and differentiation of the cells.

Get detailed information on the pathways involving JAK and how the JAK inhibiting drugs (tofacitinib) acts in controlling the progression of rheumatic diseases from this session.   

Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
 


See More Webinars @ Hidoc Webinars

See More Webinars @ Hidoc Webinars




Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot